MAP1A

Summary

MAP1A (microtubule associated protein 1A, HGNC:6835) is a protein-coding gene on chromosome 15q15.3, encoding Microtubule-associated protein 1A (P78559). Structural protein involved in the filamentous cross-bridging between microtubules and other skeletal elements.

This gene encodes a protein that belongs to the microtubule-associated protein family. The proteins of this family are thought to be involved in microtubule assembly, which is an essential step in neurogenesis. The product of this gene is a precursor polypeptide that presumably undergoes proteolytic processing to generate the final MAP1A heavy chain and LC2 light chain. Expression of this gene is almost exclusively in the brain. Studies of the rat microtubule-associated protein 1A gene suggested a role in early events of spinal cord development.

Source: NCBI Gene 4130 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 427 total — 1 pathogenic
• MANE Select transcript: NM_002373

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6835
Approved symbol	MAP1A
Name	microtubule associated protein 1A
Location	15q15.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000166963
Ensembl biotype	protein_coding
OMIM	600178
Entrez	4130

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000300231, ENST00000382031

RefSeq mRNA: 2 — MANE Select: NM_002373 NM_001411089, NM_002373

CCDS: CCDS42031, CCDS91988

Canonical transcript exons

ENST00000300231 — 6 exons

Exon	Start	End
ENSE00001490692	43529650	43529870
ENSE00001866540	43517608	43517700
ENSE00003479753	43520972	43521112
ENSE00003514716	43520641	43520723
ENSE00003638356	43521324	43529508
ENSE00003845131	43530069	43531611

Expression profiles

Bgee: expression breadth ubiquitous, 268 present calls, max score 99.89.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 87.1103 / max 7381.2848, expressed in 1538 samples.

FANTOM5 promoters (24 alternative TSS)

Promoter ID	TPM avg	Samples expressed
146306	59.0007	1266
146302	8.1973	768
146304	5.6877	825
146330	3.1113	457
146332	2.0493	311
146315	1.3622	258
146311	1.3514	154
146313	1.1941	199
146305	0.8452	383
146331	0.6874	102

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lateral nuclear group of thalamus	UBERON:0002736	99.89	gold quality
lateral globus pallidus	UBERON:0002476	99.73	gold quality
Brodmann (1909) area 10	UBERON:0013541	99.73	gold quality
CA1 field of hippocampus	UBERON:0003881	99.70	gold quality
parietal lobe	UBERON:0001872	99.68	gold quality
substantia nigra pars compacta	UBERON:0001965	99.68	gold quality
postcentral gyrus	UBERON:0002581	99.68	gold quality
substantia nigra pars reticulata	UBERON:0001966	99.64	gold quality
Brodmann (1909) area 46	UBERON:0006483	99.49	gold quality
superior vestibular nucleus	UBERON:0007227	99.46	gold quality
pons	UBERON:0000988	99.43	gold quality
entorhinal cortex	UBERON:0002728	99.40	gold quality
medulla oblongata	UBERON:0001896	99.34	gold quality
orbitofrontal cortex	UBERON:0004167	99.34	gold quality
dorsal root ganglion	UBERON:0000044	99.30	gold quality
frontal pole	UBERON:0002795	99.30	gold quality
middle frontal gyrus	UBERON:0002702	99.29	gold quality
ventral tegmental area	UBERON:0002691	99.24	gold quality
superior frontal gyrus	UBERON:0002661	99.22	gold quality
inferior olivary complex	UBERON:0002127	99.21	gold quality
dorsal plus ventral thalamus	UBERON:0001897	99.20	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	99.11	gold quality
inferior vagus X ganglion	UBERON:0005363	99.02	gold quality
subthalamic nucleus	UBERON:0001906	98.91	gold quality
cerebellar vermis	UBERON:0004720	98.53	gold quality
occipital lobe	UBERON:0002021	98.52	gold quality
paraflocculus	UBERON:0005351	98.51	gold quality
frontal cortex	UBERON:0001870	98.48	gold quality
frontal lobe	UBERON:0016525	98.48	gold quality
prefrontal cortex	UBERON:0000451	98.39	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-HCAD-13	yes	28.03
E-HCAD-1	yes	17.41
E-CURD-122	yes	14.81
E-CURD-112	yes	14.20
E-MTAB-8498	yes	13.57
E-MTAB-9467	yes	13.32
E-MTAB-9067	yes	11.57
E-ANND-3	yes	8.92

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

154 targeting MAP1A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-1-3P	99.93	72.35	1914

Literature-anchored findings (GeneRIF, showing 10)

• Data show that two regulatory factor for X box (RFX1 and 3) binding sites in exon1 of both the mouse and human microtubule-associated protein (MAP1A) gene are important for effective transcriptional repression in non-neuronal cells. (PMID:12411430)
• a novel protein-binding partner for EPAC1 and EPAC2, light chain 2 of MAP1A (microtubule-associated protein 1A) (PMID:15202935)
• MAP1A LC2 is a biological enhancer of EPAC1 activity toward Rap1 and associated downstream signaling mechanisms (PMID:15591041)
• Complexes (MAP1B heavy chain-MAP1A light chain) form through interaction of homologous domains conserved in heavy and light chains of MAP1A and MAP1B. Conserved domains of the MAP1A and MAP1B light chains account for formation of light chain heterodimers. (PMID:16996626)
• postulate that the RhoB and MAP1A/LC2 interactions facilitate endocytic vesicle trafficking and regulate the trafficking of signaling molecules (PMID:18056259)
• Using shotgun mass spectrometry, we found this protein differentially expressed in the dorsolateral prefrontal cortex from patients with schizophrenia. (PMID:19165527)
• This protein has been found differentially expressed in thalami from patients with schizophrenia. (PMID:20471030)
• results support a role for MAP1 proteins in promoting efficient retrograde trafficking of HIV-1 by stimulating the formation of stable microtubules and mediating the association of HIV-1 cores with microtubules. (PMID:25505242)
• MAP1A functions to maintain the neuronal microtubule network in the brain and mutations cause Purkinje cell degeneration. (PMID:25788676)
• analysis across Autism Spectrum Disorder and Attention Defecit Hyperactivity Disorder, identifyies microtubule-associated protein 1A (MAP1A) as a new exome-wide significant gene conferring risk for childhood psychiatric disorders. (PMID:31768057)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	map1ab	ENSDARG00000022045
danio_rerio	map1aa	ENSDARG00000059601
mus_musculus	Map1a	ENSMUSG00000027254
rattus_norvegicus	Map1a	ENSRNOG00000014230

Paralogs (2): MAP1S (ENSG00000130479), MAP1B (ENSG00000131711)

Protein

Protein identifiers

Microtubule-associated protein 1A — P78559 (reviewed: P78559)

Alternative names: Proliferation-related protein p80

All UniProt accessions (2): P78559, E9PGC8

UniProt curated annotations — full annotation on UniProt →

Function. Structural protein involved in the filamentous cross-bridging between microtubules and other skeletal elements.

Subunit / interactions. 3 different light chains, LC1 (a cleavage product of MAP1B), LC2 (a cleavage product of MAP1A) and LC3 (produced by one of the MAP1LC3 genes), can associate with the MAP1A or MAP1B heavy chains. Interacts with TIAM2. Interacts with guanylate kinase-like domain of DLG1, DLG2 and DLG4. Binds to CSNK1D. Interacts with ELAVL4.

Subcellular location. Cytoplasm. Cytoskeleton.

Tissue specificity. Brain.

Post-translational modifications. Phosphorylated by CSNK1D. LC2 is generated from MAP1A by proteolytic processing.

Domain organisation. The basic region containing the repeats may be responsible for the binding of MAP1A to microtubules.

Similarity. Belongs to the MAP1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
P78559-1	1	yes
P78559-2	2

RefSeq proteins (2): NP_001398018, NP_002364* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026074	MAP1	Family
IPR036866	RibonucZ/Hydroxyglut_hydro	Homologous_superfamily
IPR057480	MAP1A/B/S-like_MBL	Domain

Pfam: PF25281

UniProt features (191 total): modified residue 75, sequence conflict 33, compositionally biased region 32, sequence variant 27, region of interest 11, repeat 9, chain 3, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

No AlphaFold model available for P78559 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (75): 1329, 1544, 1600, 1626, 1654, 1675, 1749, 1762, 1776, 1791, 1797, 1801, 1812, 1818, 1931, 1957, 2022, 2058, 2074, 2104 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 331 (showing top): VALK_AML_WITH_FLT3_ITD, GOBP_DENDRITE_DEVELOPMENT, GOBP_MEMORY, RNGTGGGC_UNKNOWN, GOBP_PROTEIN_LOCALIZATION_TO_CYTOSKELETON, GOBP_NEGATIVE_REGULATION_OF_PROTEOLYSIS, GOBP_REGULATION_OF_PROTEASOMAL_UBIQUITIN_DEPENDENT_PROTEIN_CATABOLIC_PROCESS, GOBP_COGNITION, GOBP_AXO_DENDRITIC_TRANSPORT, MYOGENIN_Q6, GOBP_BEHAVIOR, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GCANCTGNY_MYOD_Q6, SP3_Q3

GO Biological Process (17): microtubule cytoskeleton organization (GO:0000226), axonogenesis (GO:0007409), memory (GO:0007613), associative learning (GO:0008306), dendrite development (GO:0016358), regulation of microtubule depolymerization (GO:0031114), negative regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032435), regulation of synaptic plasticity (GO:0048167), voluntary musculoskeletal movement (GO:0050882), neuron cellular homeostasis (GO:0070050), anterograde axonal protein transport (GO:0099641), retrograde axonal protein transport (GO:0099642), negative regulation of protein localization to microtubule (GO:1902817), positive regulation of protein localization (GO:1903829), neuron projection maintenance (GO:1990535), positive regulation of protein localization to cell surface (GO:2000010), nervous system development (GO:0007399)

GO Molecular Function (7): actin binding (GO:0003779), structural molecule activity (GO:0005198), microtubule binding (GO:0008017), cytoskeletal adaptor activity (GO:0008093), tubulin binding (GO:0015631), tau protein binding (GO:0048156), protein binding (GO:0005515)

GO Cellular Component (16): cytoplasm (GO:0005737), cytosol (GO:0005829), microtubule (GO:0005874), microtubule associated complex (GO:0005875), axon (GO:0030424), dendrite (GO:0030425), neuron projection (GO:0043005), neuronal cell body (GO:0043025), axon initial segment (GO:0043194), dendritic shaft (GO:0043198), dendritic branch (GO:0044307), synapse (GO:0045202), primary dendrite (GO:0150001), dendritic microtubule (GO:1901588), axon cytoplasm (GO:1904115), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoskeletal protein binding	4
cellular anatomical structure	4
dendrite	4
axo-dendritic protein transport	2
microtubule cytoskeleton	2
neuron projection	2
cytoskeleton organization	1
microtubule-based process	1
cell morphogenesis involved in neuron differentiation	1
neuron projection morphogenesis	1
axon development	1
learning or memory	1
learning	1
neuron projection development	1
anatomical structure development	1
microtubule depolymerization	1
regulation of microtubule polymerization or depolymerization	1
regulation of protein depolymerization	1
regulation of supramolecular fiber organization	1
regulation of proteasomal ubiquitin-dependent protein catabolic process	1
proteasome-mediated ubiquitin-dependent protein catabolic process	1
negative regulation of proteasomal protein catabolic process	1
negative regulation of ubiquitin-dependent protein catabolic process	1
modulation of chemical synaptic transmission	1
regulation of biological quality	1
musculoskeletal movement	1
cellular homeostasis	1
anterograde axonal transport	1
protein localization to presynapse	1
retrograde axonal transport	1
protein localization to microtubule	1
regulation of protein localization to microtubule	1
negative regulation of protein localization	1
intracellular protein localization	1
regulation of protein localization	1
positive regulation of biological process	1
neuron projection organization	1
protein localization to cell surface	1
positive regulation of protein localization	1
regulation of protein localization to cell surface	1

Protein interactions and networks

STRING

1894 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MAP1A	SQSTM1	Q13501	994
MAP1A	BECN1	Q14457	947
MAP1A	BNIP3L	O60238	940
MAP1A	FUNDC1	Q8IVP5	936
MAP1A	BNIP3	Q12983	935
MAP1A	ATG12	O94817	928
MAP1A	F5GZY7	F5GZY7	926
MAP1A	GABARAPL2	P60520	923
MAP1A	MAP1LC3B	Q9GZQ8	919
MAP1A	CD300C	Q08708	912
MAP1A	ATG5	Q9H1Y0	905
MAP1A	CALCOCO2	Q13137	896
MAP1A	ATG3	Q9NT62	875
MAP1A	ATG7	O95352	866
MAP1A	ATG16L1	Q676U5	849

IntAct

82 interactions, top by confidence:

A	B	Type	Score
SFN	RAF1	psi-mi:“MI:0915”(physical association)	0.890
MAP1LC3B	ATG7	psi-mi:“MI:0914”(association)	0.740
MAP1LC3B	MAP1B	psi-mi:“MI:0914”(association)	0.730
DIDO1	OGT	psi-mi:“MI:0914”(association)	0.670
NUFIP1	PDE2A	psi-mi:“MI:0914”(association)	0.530
SREK1IP1	KPNA5	psi-mi:“MI:0914”(association)	0.530
MAP1LC3B	NIPSNAP2	psi-mi:“MI:0914”(association)	0.520
MAP1A	Kcnma1	psi-mi:“MI:0915”(physical association)	0.510
Kcnma1	MAP1A	psi-mi:“MI:0915”(physical association)	0.510
DISC1	MAP1A	psi-mi:“MI:0915”(physical association)	0.510
SHANK3	MAP1A	psi-mi:“MI:0915”(physical association)	0.500
MAP1A	Csnk1d	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
MAP1A	Dlg4	psi-mi:“MI:0407”(direct interaction)	0.440
MAP1A	PLEC	psi-mi:“MI:0915”(physical association)	0.400
CACNB4	MAP1A	psi-mi:“MI:0915”(physical association)	0.370
HTR2A	MAP1A	psi-mi:“MI:0915”(physical association)	0.370
MAP1A	RHOB	psi-mi:“MI:0915”(physical association)	0.370
JUN		psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
PA	RBMX	psi-mi:“MI:0914”(association)	0.350
PB2	HAX1	psi-mi:“MI:0914”(association)	0.350
APBB1	SSPOP	psi-mi:“MI:0914”(association)	0.350
TP63	HNRNPR	psi-mi:“MI:0914”(association)	0.350
TRAF3IP1	PHGDH	psi-mi:“MI:0914”(association)	0.350
BMI1	HMGB1P1	psi-mi:“MI:0914”(association)	0.350
MAP1LC3A	ATG7	psi-mi:“MI:0914”(association)	0.350
MAP1LC3B	MAP1LC3B2	psi-mi:“MI:0914”(association)	0.350
MAP1LC3A		psi-mi:“MI:0914”(association)	0.350

BioGRID (124): MAP1A (Two-hybrid), MAP1A (Affinity Capture-MS), MAP1A (Affinity Capture-MS), MAP1A (Affinity Capture-MS), MAP1A (Affinity Capture-MS), MAP1A (Affinity Capture-MS), MAP1A (Affinity Capture-MS), ACTA1 (Reconstituted Complex), MAP1A (Affinity Capture-MS), MAP1A (Affinity Capture-MS), MAP1A (Affinity Capture-RNA), MAP1A (Affinity Capture-Western), MAP1A (Two-hybrid), MAP1A (Reconstituted Complex), MAP1A (Affinity Capture-Western)

ESM2 similar proteins: A0A8I5ZN27, A6NNT2, D3ZEN0, E1AZ71, E1BM58, O15061, O15446, O55103, O88737, O88778, P08855, P0C671, P10636, P10637, P12036, P16884, P19246, P19332, P27816, P34926, P36225, P53814, P62521, P78559, Q06002, Q09666, Q0VA45, Q28181, Q3TN34, Q3UH66, Q4R729, Q5S6V2, Q5STT6, Q5T0Z8, Q5YCV9, Q5YCW0, Q5YCW1, Q63425, Q76KJ5, Q7Z2K8

Diamond homologs: A6QQ70, P0C5W1, P14400, P14401, P14873, P15205, P34926, P46821, P78559, Q66K74, Q8C052, Q9QYR6, Q9W596

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
estramustine	“down-regulates activity”	MAP1A	“chemical inhibition”
DYRK1A	“up-regulates activity”	MAP1A	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 101 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
mitophagy	6	23.3×	9e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

427 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	391
Likely benign	28
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1685937	NM_002373.6(MAP1A):c.5484_5485del (p.Met1829fs)	Pathogenic

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

18195 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:43521492:T:C	F7L	1.000
15:43521493:T:C	F7S	1.000
15:43521493:T:G	F7C	1.000
15:43521494:C:A	F7L	1.000
15:43521494:C:G	F7L	1.000
15:43521505:T:A	V11D	1.000
15:43521544:T:C	L24P	1.000
15:43521567:T:C	F32L	1.000
15:43521569:C:A	F32L	1.000
15:43521569:C:G	F32L	1.000
15:43521571:T:A	L33H	1.000
15:43521571:T:C	L33P	1.000
15:43521573:A:G	K34E	1.000
15:43521575:G:C	K34N	1.000
15:43521575:G:T	K34N	1.000
15:43521577:T:A	L35H	1.000
15:43521577:T:C	L35P	1.000
15:43521586:C:A	P38H	1.000
15:43521590:T:G	C39W	1.000
15:43521591:T:C	C40R	1.000
15:43521592:G:A	C40Y	1.000
15:43521593:C:G	C40W	1.000
15:43521600:T:C	F43L	1.000
15:43521601:T:C	F43S	1.000
15:43521602:C:A	F43L	1.000
15:43521602:C:G	F43L	1.000
15:43521615:G:A	G48R	1.000
15:43521615:G:C	G48R	1.000
15:43521615:G:T	G48W	1.000
15:43521624:G:C	A51P	1.000

dbSNP variants (sampled 300 via entrez): RS1000015402 (15:43526154 A>G), RS1000138380 (15:43518167 A>C), RS1000408356 (15:43511934 A>C), RS1000468510 (15:43519092 G>C), RS1000489139 (15:43518443 C>T), RS1000509616 (15:43531102 C>T), RS1000565559 (15:43524327 G>C), RS1000634323 (15:43518783 A>C,G), RS1000688469 (15:43527122 T>C), RS1000689835 (15:43513529 CT>C), RS1001174921 (15:43530788 A>C), RS1001204238 (15:43520628 A>C,G), RS1001360485 (15:43510991 G>A,T), RS1001471836 (15:43517947 A>G), RS1002260308 (15:43512960 G>A)

Disease associations

OMIM: gene MIM:600178 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST004603_232	Platelet count	2.000000e-23
GCST004607_107	Plateletcrit	2.000000e-26
GCST006613_79	Triglycerides	5.000000e-28
GCST007849_8	Triglycerides	1.000000e-17
GCST010083_192	Hemoglobin levels	8.000000e-35
GCST010083_271	Hemoglobin levels	4.000000e-36
GCST011925_4	Triglyceride levels x fish oil supplementation interaction (2df)	2.000000e-13

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004309	platelet count
EFO:0007985	platelet crit
EFO:0004530	triglyceride measurement
EFO:0004509	hemoglobin measurement
EFO:0600007	fish oil supplement exposure measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

61 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression	4
(+)-JQ1 compound	increases expression	3
mercuric bromide	increases expression, affects cotreatment	2
bisphenol S	increases expression, affects cotreatment, decreases expression	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	2
Dexamethasone	increases expression, affects cotreatment, decreases expression	2
Estradiol	increases expression, affects cotreatment, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Valproic Acid	affects expression, increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
Particulate Matter	decreases expression, increases abundance, affects expression	2
OTX015	increases expression	1
FR900359	affects phosphorylation	1
bisphenol F	increases expression	1
mivebresib	increases expression	1
sotorasib	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
lead acetate	increases expression	1
pyrimidin-2-one beta-ribofuranoside	increases expression	1
trichostatin A	affects expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
monomethylarsonous acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
bisphenol B	increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
licochalcone B	increases expression	1
trametinib	affects cotreatment, increases expression	1
NVP-BKM120	affects cotreatment, increases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SW29	HAP1 MAP1A (-) 1	Cancer cell line	Male
CVCL_SW30	HAP1 MAP1A (-) 2	Cancer cell line	Male
CVCL_SW31	HAP1 MAP1A (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice